A computer program developed by GNS Healthcare could be used to model and predict disease progression and response to treatment in people with multiple myeloma. Called “Gemini, the in silico ” Patient” (“in silico” refers to analyses done using computer simulation), the program was built through a collaboration between multiple biopharmaceutical companies, academic medical centers, and…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Reolysin-Kyprolis Combo Elicits Promising Clinical Responses in Phase 1B Trial
When given in combination with Kyprolis (carfilzomib), the investigative therapy Reolysin (pelareorep) elicits a strong inflammatory response — and promising clinical responses — in people with relapsed or refractory multiple myeloma, a Phase 1b trial shows. The study’s findings were presented in a poster, titled “Oncolytic virus Pelareorep plus Carfilzomib & Dexamethasone phase I trial in Carfilzomib-refractory patients…
FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients
Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for hard-to-treat patients with multiple myeloma. The application is specific for people with triple-refractory disease — those who failed to respond to at least one immunomodulatory agent (IMiD), one proteasome inhibitor, and one anti-CD38 monoclonal…
EMA to Review Liso-cel as CAR T-cell Therapy for Advanced Lymphomas
The European Medicines Agency (EMA) has agreed to review a request to approve the investigational CAR T-cell therapy, lisocabtagene maraleucel (liso-cel), for people with pretreated lymphomas. The marketing authorization application, submitted by Bristol Myers Squibb, is specific to patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), and follicular lymphoma…
Imfinzi Plus Chemo Aids Survival in Inoperable Pleural Mesothelioma, Phase 2 Data Show
Adding Imfinzi (durvalumab) to standard first-line chemotherapy prolongs survival for adults newly diagnosed with inoperable malignant pleural mesothelioma, according to data from a Phase 2 clinical trial. This study is the first to show survival times exceeding 20 months in this patient population. A Phase 3 trial, called DREAM3R (NCT04334759), to confirm the combination’s superiority over…
FDA Grants Priority Review to Keytruda for Relapsed or Refractory Classical Hodgkin’s Lymphoma
The U.S. Food and Drug Administration (FDA) has accepted and given priority review to Merck‘s application requesting the approval of Keytruda (pembrolizumab) as a second-line treatment for adults with relapsed or refractory classical Hodgkin’s lymphoma (cHL). The supplemental biologics license application was based on data from the Phase 3 KEYNOTE-204 clinical trial (NCT02684292), in which Keytruda significantly…
Uppsala in Last Preclinical Stage for New CAR T-cell Product for Glioblastoma
Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy for glioblastoma, an aggressive form of brain cancer that is often difficult to treat. Their project is now entering the final preclinical stage of development, according…
First-line Tislelizumab Plus Chemo Under Review in China for Advanced NSCLC
The Chinese Center for Drug Evaluation (CDE) of the National Medical Products Administration has accepted for review Beigene’s application seeking approval for tislelizumab, in combination with standard chemotherapy, as a first-line treatment for people with advanced non-squamous non-small cell lung cancer (NSCLC). This is Beigene’s second supplemental new drug application (sNDA) in China for its experimental candidate tislelizumab. The…
EMA Grants Trastuzumab Deruxtecan Accelerated Assessment for Advanced HER2-positive Breast Cancer
The European Medicines Agency (EMA) has validated Daiichi Sanyoko‘s marketing authorization application for trastuzumab deruxtecan (DS-8201) for the treatment of inoperable or metastatic HER2-positive breast cancer, the company announced. The validation means that the application is complete and may now begin the scientific review process by the Committee for Medicinal Products for Human Use. The…
Tecentriq-Chemo Combo Ups Percentage of TNBC Patients With No Cancer at Surgery
When given alongside chemotherapy, Tecentriq (atezolizumab) increases the percentage of people with early triple-negative breast cancer (TNBC) who show no signs of cancer during tumor removal surgery, a Phase 3 trial shows. These results were found regardless of the patient’s PD-L1 status, or the amount of the PD-L1 protein on the individual’s cancer cells. The study,…
Cryotherapy May Ably Treat Intermediate-risk Prostate Cancer
Cryotherapy directed to the cancerous part of the prostate may be an effective and less invasive treatment option for men with intermediate-risk, unilateral prostate cancer, without the common side effects of traditional approaches, a small study suggests. The procedure was well tolerated, and 80% of the men were free of clinically significant disease at six and…
Collaboration Seeks to Reduce Prostate Cancer Disparities in African Americans
The Prostate Cancer Foundation (PCF) and Robert F. Smith, chairman and CEO of Vista Equity Partners are supporting research on a new non-invasive genetic test to determine a man’s risk of developing prostate cancer. Named the Smith Polygenic Risk Test for Prostate Cancer, the tool is part of PCF’s large initiative to reduce prostate cancer…